Official Journal of Research Center for Gastroenterology and Liver Diseases
OpenAlex
Works that cite this article, indexed by OpenAlex.
The food plant Silybum marianum (L.) Gaertn.: Phytochemistry, Ethnopharmacology and clinical evidence
Journal of Ethnopharmacology 265 (2020)
Ilias Marmouzi; Abdelhakim Bouyahya; Shahira M. Ezzat; Meryem El Jemli; Mourad Kharbach
Antiviral Activities of Silymarin and Derivatives
Molecules 24(8) (2019)
Ching‐Hsuan Liu; Alagie Jassey; Hsin-Ya Hsu; Liang Lin
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection
Viruses 7(11) (2015)
Mirjam B. Zeisel; Émilie Crouchet; Thomas F. Baumert; Catherine Schuster
Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection
Hepatology 57(3) (2012)
Stephen J. Polyak; Péter Ferenci; Jean–Michel Pawlotsky
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B
Hepatology 57(3) (2013)
Katharina Esser‐Nobis; Inés Romero‐Brey; Tom M. Ganten; Jérôme Gouttenoire; Christian Harak; Rahel Klein; Peter Schemmer; Marco Binder; Paul Schnitzler; Darius Moradpour; Ralf F. W. Bartenschlager; Stephen J. Polyak; Wolfgang Stremmel; François Pénin; Christoph Eisenbach; Volker Lohmann
Host-targeting therapies for hepatitis C virus infection: current developments and future applications
Therapeutic Advances in Gastroenterology 11 (2018)
Émilie Crouchet; Florian Wrensch; Catherine Schuster; Mirjam B. Zeisel; Thomas F. Baumert
Sustained virological response with intravenous silibinin: individualized IFN ‐free therapy via real‐time modelling of HCV kinetics
Liver International 35(2) (2014)
Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J. Cotler; Massimo D’Amato; Ralf T. Pohl; Gali Weiss; Yaakov Jack Ashkenazi; Thomas E. Tichler; Eran Goldin; Yoav Lurie
Hepatitis C virus infection and tight junction proteins: The ties that bind
Biochimica et Biophysica Acta (BBA) - Biomembranes 1862(7) (2020)
Laurent Mailly; Thomas F. Baumert
How to optimize HCV therapy in genotype 2 patients
Liver International 33(s1) (2013)
Eleonora Grassi; Alessio Aghemo
A Comprehensive Review on the Antibacterial, Antifungal, Antiviral, and Antiparasitic Potential of Silybin
Antibiotics 13(11) (2024)
José Lima Pereira Filho; Amanda Graziela Gonçalves Mendes; Carmem Duarte Lima Campos; Israel Viegas Moreira; Cinara R. A. V. Monteiro; Suzany H. S. Soczek; Elizabeth Soares Fernandes; Rafael Cardoso Carvalho; Valério Monteiro‐Neto
Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury
BMC Complementary Medicine and Therapies 25(1) (2025)
Kasra Shahsavari; Shireen Shams Ardekani; Mohammad Reza Shams Ardekani; Majid Mokaber‐Esfahani; Hossein Kazemizadeh; Tannaz Jamialahmadi; Mehrdad Iranshahi; Mahnaz Khanavi; Maede Hasanpour
Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial
Transplant International 27(7) (2014)
Maria Grazia Rendina; Massimo D’Amato; Antonino Castellaneta; Nicola Maurizio Castellaneta; Nadia Brambilla; Giampaolo Giacovelli; Lucio Claudio Rovati; Salvatore Fabio Rizzi; Marianna Zappimbulso; R. Bringiotti; Alfredo Di Leo
Silibinin: An old drug in the high tech era of liver transplantation
Journal of Hepatology 58(3) (2012)
Péter Ferenci; Sandra Beinhardt
Silybin for Liver Diseases via Anti-Oxidative Stress: A Comprehensive Review
The American Journal of Chinese Medicine 54(01) (2026)
Chao Cui; Jingfei Shi; Yu Sun; Shuai Gao; Kai Wang